Sten Verland, PhD, is a co-founder of Sunstone Life Science Ventures and served as a General Partner for 17 years before. See sector focus and contact routes.
Sten Verland, PhD, is a co-founder of Sunstone Life Science Ventures and served as a General Partner for 17 years before transitioning to a part-time Venture Partner role. He holds a PhD in Immunology and a master’s degree in Biology and Mathematics from the University of Copenhagen. Sunstone invests in early-stage life science companies developing novel human therapeutics, focusing on Series A and B rounds across Europe. The firm manages approximately €500M across four funds and is one of the largest Nordic life science investors. Verland’s portfolio includes immuno-oncology company STipe Therapeutics, which Sunstone announced an investment in in 2019. While specific check sizes and lead/follow behavior for Verland individually are not publicly detailed, Sunstone typically backs drug development companies at Series A/B. No distinctive public writing or unique point of view by Verland is documented in the available sources.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in Copenhagen.
Investors like Sten Verland · Full investor directory · Investor access · Company funding database